Table 2.
Overall accuracy of circulating biomarkers in comparison of EUS-FNA for the diagnosis of pancreatic cancer (n = 105)
| Primary tumor | Circulating biomarkers | ||||
| EUS-FNA | EUS-FNA + ddPCR (KRAS) | ctDNA (KRAS) | CA19-9 | EUS-FNA + CA19-9 | |
| Sensitivity (%) | 71.4 | 91.6 | 35.2 | 71.2 | 79.6 |
| Specificity (%) | 86.4 | 80.9 | 88.6 | 78.3 | 75.9 |
| PPV (%) | 92.6 | 92.5 | 88.1 | 91.2 | 85.4 |
| NPV (%) | 55.9 | 79.1 | 36.4 | 46.7 | 71.0 |
| Accuracy (%) | 75.8 | 88.6 | 51.0 | 73.0 | 79.5 |
| ROC AUC | 0.765 | 0.889 | 0.614 | 0.683 | 0.830 |
CA19-9, carbohydrate antigen 19-9; ctDNA, circulating tumor DNA; EUS-FNA, endoscopic ultrasound-guided fine-needle aspiration; NPV, negative predictive value; PPV, positive predictive value; ROC AUC, area under the curve of the receiver operating characteristic curve; combination: the combination of EUS-FNA and CA19-9.